{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:42:23Z","timestamp":1792237343573,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:20:02Z","timestamp":1792236002000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6112-116X","authenticated-orcid":false,"given":"Joseph","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Hakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"K.C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hernan","year":"2010","journal-title":"Epidemiology"},{"issue":"22","key":"10.1016\/j.urolonc.2026.09.015_bib0002","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0003","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"15","key":"10.1016\/j.urolonc.2026.09.015_bib0004","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.09.015_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.urolonc.2026.09.015_bib0007","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdy075","article-title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","volume":"29","author":"Liang","year":"2018","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.09.015_bib0008","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.urolonc.2026.09.015_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.09.015_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.09.015_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.09.015_bib0012","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.09.015_bib0013","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.annonc.2026.02.017","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial","volume":"37","author":"Choueiri","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0015","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.09.015_bib0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab plus axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.015_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0021","unstructured":"Centers for Medicare & Medicaid Services. ASP pricing files. Updated 2025 Oct 12. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed December 5, 2025."},{"key":"10.1016\/j.urolonc.2026.09.015_bib0022","unstructured":"U.S. Department of Health and Human Services, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0; 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development. Accessed December 5, 2025."},{"issue":"19","key":"10.1016\/j.urolonc.2026.09.015_bib0023","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111900","article-title":"Assessment of traditional and novel effect measures for time-to-event endpoints: a meta-epidemiological study of published oncological trials","volume":"186","author":"Huang","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-025-01194-w","article-title":"Time-dependent comparative effectiveness of first-line treatment for metastatic clear cell renal cell carcinoma: a restricted mean survival Time-based network meta-analysis","volume":"21","author":"Fukushima","year":"2026","journal-title":"Target Oncol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2026.06.003","article-title":"First-line therapy for metastatic renal cell carcinoma: an updated network meta-analysis using final follow-up data","author":"Yanagisawa","year":"2026","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2026.09.015_bib0027","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jrsm.1539","article-title":"A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis","volume":"13","author":"Daly","year":"2022","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.urolonc.2026.09.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102773","article-title":"Treatment decision-making and quality of life versus length of life preferences of older patients with early stage cancer: a systematic review","volume":"16","author":"Martin","year":"2025","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0029","first-page":"237","article-title":"Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits","volume":"25","author":"Fallowfield","year":"2017","journal-title":"Support Care Cancer"},{"issue":"14\u201315","key":"10.1016\/j.urolonc.2026.09.015_bib0030","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/sim.4780111409","article-title":"The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis","volume":"11","author":"Wei","year":"1992","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.015_bib0031","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/sim.9259","article-title":"Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model","volume":"41","author":"Austin","year":"2022","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.015_bib0033","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.015_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after Immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0035","article-title":"Statistical considerations in long-term efficacy evaluation of anti-cancer therapies","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2026.09.015_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1072634","article-title":"Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis","volume":"13","author":"Qin","year":"2023","journal-title":"Front Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600743X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600743X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:20:09Z","timestamp":1792236009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600743X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S107814392600743X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}